NKX2-1 and neoplasm: KrasG12D activation with concomitant Nkx2-1 deletion (KrasLSL-G12D/+; Nkx2-1F/F) together with either Foxa1 or Foxa2 disruption was reported to promote squamous differentiation of tumor lesions (Camolotto et al. 2018).